Skip to main content

Table 4 Acute and late toxicity

From: Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity

 

Grade 1–2

Grade 3

Grade 4

Acute (≤ 3 months post-treatment) toxicity incidence in N = 37 patients

NONE

N = 11 (30%)

 Diarrhoea

N = 5 (14%)

0

0

 Nausea

N = 8 (22%)

0

0

 Vomiting

N = 2 (5%)

0

0

 Dyspepsia

N = 2 (5%)

0

0

 Anorexia

N = 2 (5%)

0

0

 Pain

N = 7 (19%)

N = 1 (3%)

0

 Fatigue

N = 11 (30%)

N = 1 (3%)

0

 Jaundice

N = 1 (3%)

0

0

 Obstructive Jaundice

0

N = 1 (3%)

0

Late (>  3 months post-treatment) toxicity incidence in N = 32

NONE

N = 27 (84%)

 Pain

N = 1 (3%)*

0

0

 Nausea

N = 1 (3%)*

0

0

 Pancreatic Insufficiency

N = 1 (3%)

0

0

 GI Bleeding

0

0

N = 2 (6%)

 Duodenal Stricture

0

0

N = 2 (6%)

  1. *one patient experienced Grade 2 pain and Grade 2 nausea